GALAFOLD Drug Patent Profile

« Back to Dashboard

When do Galafold patents expire, and when can generic versions of Galafold launch?

Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are sixty-six patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in GALAFOLD is migalastat hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the migalastat hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Galafold

Galafold was eligible for patent challenges on August 10, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 16, 2039. This may change due to patent challenges or generic licensing.

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GALAFOLD

US Patents:	66
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	10
Patent Applications:	378
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GALAFOLD
What excipients (inactive ingredients) are in GALAFOLD?	GALAFOLD excipients list
DailyMed Link:	GALAFOLD at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GALAFOLD

Constraining patent/regulatory exclusivity:

11,826,360

NDA:

208623

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GALAFOLD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amicus Therapeutics	Phase 3
Amicus Therapeutics	Phase 2

See all GALAFOLD clinical trials

Paragraph IV (Patent) Challenges for GALAFOLD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GALAFOLD	Capsules	migalastat hydrochloride	123 mg	208623	3	2022-08-10

US Patents and Regulatory Information for GALAFOLD

GALAFOLD is protected by sixty-seven US patents.

This potential generic entry date is based on patent 11,826,360.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	10,792,279
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	10,849,889
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,278,537

International Patents for GALAFOLD

When does loss-of-exclusivity occur for GALAFOLD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GALAFOLD around the world.

Country	Patent Number	Title	Estimated Expiration
China	109069494
China	114159436
European Patent Office	3432882

Supplementary Protection Certificates for GALAFOLD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2787345	300843	Netherlands		PRODUCT NAME: MIGALASTAT OF EEN ZOUT DAARVAN, WAARONDER HET HYDROCHLORIDEZOUT; REGISTRATION NO/DATE: EU/1/15/1082 20160531
2787345	PA2016033	Lithuania		PRODUCT NAME: MIGALASTATAS ARBA JO DRUSKA, ISKAITANT IR HIDROCHLORIDO DRUSKA; REGISTRATION NO/DATE: EU/1/15/1082 20160526
2787345	122016000090	Germany		PRODUCT NAME: MIGALASTAT ODER EIN SALZ DAVON, EINSCHLIESSLICH DES HYDROCHLORIDSALZES; REGISTRATION NO/DATE: EU/1/15/1082/001 20160526

Galafold Market Dynamics, Revenue Growth, Patent Exclusivity, and Generic Risk

Last updated: October 9, 2026

Galafold, the brand name for migalastat hydrochloride, is Amicus Therapeutics’ lead commercial product for Fabry disease. Its market position depends on three factors: a genetically defined patient population, an oral alternative to enzyme replacement therapy, and the need to confirm that a patient’s GLA mutation is amenable to pharmacological chaperone treatment. Galafold generated approximately $403 million in global revenue in 2023, up from about $358 million in 2022, according to Amicus’ annual reporting. [1]

The product has regulatory approval in the United States, European Union, Japan and other markets. U.S. orphan-drug exclusivity began with FDA approval on May 10, 2018 and generally extended through May 10, 2025, subject to statutory conditions and any applicable pediatric extension. Patent protection may extend beyond regulatory exclusivity, making patent expiry and potential Abbreviated New Drug Application, or ANDA, challenges more important than the orphan exclusivity date alone.

What is Galafold and how does it compete in Fabry disease?

Galafold is an oral pharmacological chaperone containing migalastat. It is indicated for adults with Fabry disease who have an amenable GLA variant. The drug stabilizes certain mutant forms of alpha-galactosidase A, allowing the enzyme to reach lysosomes and improve substrate processing. [2]

Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene. Commercial treatment has historically centered on enzyme replacement therapies, including Fabra زyme, Replagal and Elfabrio. Galafold differs from those products because it is administered orally rather than by intravenous infusion.

Product	Active treatment	Administration	Primary commercial distinction
Galafold	Migalastat	Oral capsule every other day	Available only for amenable GLA variants
Fabrazyme	Agalsidase beta	Intravenous infusion	Broad established use, infusion burden
Replagal	Agalsidase alfa	Intravenous infusion	Regional availability, mainly outside the U.S.
Elfabrio	Pegunigalsidase alfa	Intravenous infusion	Newer long-acting enzyme replacement option

Galafold’s addressable market is smaller than the total Fabry population because treatment requires a qualifying amenable mutation. Amicus reports that approximately 35% to 50% of patients with Fabry disease may have amenable mutations, depending on the population and testing methodology. [1,3]

How large is the Galafold market?

The commercial market is concentrated in rare-disease centers, specialist prescribers and reimbursement systems that support genetic testing. The product has expanded through geographic launches and patient conversion from enzyme replacement therapy.

Amicus reported the following Galafold net product sales:

Fiscal year	Galafold revenue	Approximate annual growth
2020	$223 million	59%
2021	$306 million	37%
2022	$359 million	17%
2023	$403 million	12%

Figures are rounded and based on Amicus annual reports and earnings disclosures. [1,4,5]

Growth has decelerated as the product has matured in major markets. The principal growth drivers remain new patient diagnosis, genetic testing, treatment conversion and expansion in countries where reimbursement has improved. The main restraints are the limited prevalence of Fabry disease, mutation eligibility and competition from established enzyme replacement products.

What drives Galafold revenue?

Galafold revenue is driven by four commercial variables:

1. The number of diagnosed Fabry patients.
2. The percentage of patients with amenable mutations.
3. The rate of treatment initiation and conversion.
4. Net price after government rebates, discounts and patient-support programs.

Pricing is difficult to compare directly across countries because rare-disease reimbursement contracts are confidential and public prices vary by market. The commercial model is largely specialty-pharmacy and reimbursement-based, with Amicus supporting patient identification, mutation testing and access services.

The product’s oral dosing has economic value for patients who face repeated infusion visits. That advantage can support conversion, although clinical guidelines and prescriber decisions continue to depend on renal status, disease manifestations, prior enzyme replacement use and individual mutation characteristics.

When does Galafold lose regulatory exclusivity?

U.S. FDA approval occurred on May 10, 2018. Galafold received orphan-drug designation for Fabry disease. Orphan-drug exclusivity generally lasts seven years from approval, placing the base expiration date around May 10, 2025. [2,6]

Exclusivity category	Relevant date or period	Commercial effect
FDA approval	May 10, 2018	U.S. commercial launch
New chemical entity exclusivity	Generally five years	Expired in 2023, subject to applicable challenge rules
Orphan-drug exclusivity	Generally seven years	Approximately through May 10, 2025
Patent protection	Patent-specific	May continue after regulatory exclusivity
Pediatric extension	Six months if granted and applicable	Could extend qualifying exclusivity periods

Orphan exclusivity does not prevent every competing product from entering the market. It generally blocks FDA approval of the same drug for the same orphan indication, subject to statutory exceptions. A product with a different active ingredient, a different indication or a legally sufficient showing may not be barred in the same way.

What patents protect Galafold?

Galafold’s patent estate is built around migalastat, its use in treating Fabry disease, mutation-specific patient selection and pharmaceutical formulations. The key commercial protection is not limited to the chemical compound. Method-of-use and patient-selection claims can remain relevant because Galafold is restricted to patients with amenable GLA variants.

The relevant patent categories include:

Patent category	Subject matter	Competitive significance
Compound patents	Migalastat and related chemical forms	Protect the active pharmaceutical ingredient
Salt and solid-form patents	Hydrochloride salt and crystalline forms	Can complicate formulation substitution
Method-of-treatment patents	Use in Fabry disease	Relevant to branded and generic labeling
Patient-selection patents	Treatment of patients with amenable GLA variants	Supports mutation-specific prescribing
Formulation patents	Oral dosage forms and excipients	May restrict close pharmaceutical copies
Manufacturing patents	Synthesis, purification and solid-state processes	Can raise cost and process-development barriers

The practical patent question is whether an ANDA applicant can obtain approval with a Paragraph IV certification, a non-infringing formulation, a different manufacturing process or a label that avoids protected uses. Patent term depends on the individual U.S. patent, patent-term adjustment, terminal disclaimers and any patent-term extension. FDA Orange Book listings, USPTO records and Amicus’ current SEC disclosures should be read together rather than treating one patent date as the end of all protection. [1,7]

What is the Orange Book status of Galafold?

Galafold is a small-molecule prescription drug and is evaluated through the FDA drug-approval framework applicable to small molecules, not the biosimilar pathway. Any relevant listed patents, exclusivity periods and therapeutic-equivalence information are reflected through FDA’s Orange Book and associated FDA records. [7]

The commercial risk is greater if an Orange Book-listed patent covers the approved product itself or a required use. A method-of-use listing may be challenged through a Paragraph IV certification, but an ANDA applicant must still manage labeling, certification and potential litigation exposure.

Are generic companies challenging Galafold patents?

A Paragraph IV challenge is the principal route for an ANDA applicant seeking to market a generic before expiration of an Orange Book-listed patent. Publicly reported litigation and regulatory records should be monitored for:

• ANDA filings containing Paragraph IV certifications;
• a 45-day patent-infringement action by Amicus;
• a potential 30-month stay of FDA approval;
• settlements that grant a future launch date;
• skinny-label strategies excluding protected indications or uses.

As of the public company disclosures and regulatory sources cited here, Galafold had not produced a widely disclosed generic settlement comparable to major primary-care products. The absence of a public settlement does not establish that no confidential challenge or non-public patent correspondence exists.

What generic launch scenarios exist?

The principal scenarios are:

Scenario	Likely timing	Market impact
No viable ANDA challenge	After relevant patent and exclusivity expiry	Continued branded pricing, slower erosion
Paragraph IV litigation	Before patent expiry	Launch depends on court outcome or settlement
Authorized generic or negotiated entry	Contract-specific	Controlled erosion and possible royalty economics
Skinny-label generic	After non-protected uses are removed	Limited substitution and slower uptake
Full generic entry	After enforceable protection expires	Rapid price and volume pressure

Generic substitution could be slower than in a high-volume chronic-care market because Fabry treatment is managed by specialists, patients are genetically screened and prescribers may be reluctant to switch a stable patient. Pharmacy substitution, reimbursement policy and the extent of payer contracting would still influence erosion.

Is Galafold exposed to biosimilar competition?

No. Galafold is a small-molecule drug, not a biologic. Biosimilar competition under the Public Health Service Act is therefore not the relevant pathway. Competitive entry would generally occur through an ANDA or another small-molecule approval route, subject to formulation, labeling, patent and exclusivity requirements.

Galafold does compete against biologic enzyme replacement therapies, including biosimilar or follow-on versions of enzyme products if those products obtain approval. That is indirect competitive pressure rather than biosimilar competition against migalastat itself.

How strong is the Galafold patent estate?

The estate is commercially stronger than a single compound patent because Galafold combines several protection layers:

• a defined chemical product;
• a narrow but clinically important patient population;
• mutation-specific treatment selection;
• an oral dosage form;
• manufacturing and solid-state claims.

Its weakness is the narrow disease market and the potential difficulty of proving infringement for some method-of-use claims. If a competitor can develop a non-infringing process, formulate a product outside relevant claims or use a label that excludes protected treatment, patent protection may be less effective than the branded product’s clinical differentiation.

The product’s regulatory and commercial barriers are also meaningful. A competitor must establish pharmaceutical equivalence, bioequivalence and appropriate labeling. It must also reach a small specialist market with genetic-testing infrastructure and reimbursement access. Those barriers can delay or reduce generic penetration but do not replace patent protection.

What patent litigation affects Galafold?

The key litigation risk is future ANDA litigation involving Amicus and a generic applicant. The likely issues would include:

1. Whether the generic product infringes compound, formulation or use claims.
2. Whether an asserted patent is valid over prior art.
3. Whether the claims are enabled and adequately described.
4. Whether the generic label induces infringement.
5. Whether a 30-month stay delays FDA approval.
6. Whether a settlement permits an agreed launch before patent expiry.

No major publicly disclosed court decision has established a definitive invalidity ruling that removes all Galafold protection. Litigation status can change quickly after a Paragraph IV notice and should be reviewed through PACER, FDA records and Amicus’ quarterly filings.

Has Amicus licensed or partnered Galafold?

Amicus has retained primary commercial control of Galafold and has built its rare-disease infrastructure around the product. Regional distribution and commercialization arrangements may exist in individual markets, but Galafold is not generally characterized as a product dependent on a single global co-commercialization partner.

The company’s strategic objective has been to use Galafold cash flow to support expansion of its rare-disease portfolio, including Joenja, its treatment for activated phosphoinositide 3-kinase delta syndrome. This creates a portfolio-level financial relationship: Galafold funds the business, while future growth depends increasingly on diversification. [1]

What is the FDA regulatory status of Galafold?

Galafold is FDA-approved for adults with Fabry disease who have an amenable GLA variant. The FDA label includes a mutation-amenability framework and requires use in the appropriate genetically defined population. [2]

The regulatory profile creates both protection and limitation. The mutation requirement supports clinical differentiation and reduces direct interchangeability with enzyme replacement products. It also restricts the addressable population and makes diagnosis, sequencing and interpretation central to demand.

The European Medicines Agency authorized Galafold for long-term treatment of adults and adolescents aged 12 years and older in certain jurisdictions, subject to the applicable product information. [3] Regional labels and age ranges should not be assumed to be identical to the U.S. label.

How does Galafold compare financially with competing Fabry drugs?

Galafold has a different revenue model from enzyme replacement therapies. Enzyme products generate recurring infusion-center utilization and can benefit from broad mutation eligibility. Galafold generates oral-drug revenue from a smaller genetically selected population.

Factor	Galafold	Enzyme replacement therapy
Delivery	Oral	Intravenous
Patient eligibility	Amenable GLA mutations	Generally broader
Treatment setting	Home or outpatient oral use	Infusion center or supervised setting
Switching friction	Genetic eligibility and clinical response	Established infusion protocols
Generic or biosimilar risk	Small-molecule ANDA risk	Biologic follow-on or biosimilar risk
Commercial advantage	Convenience and oral administration	Longer treatment history and broader eligibility

Galafold’s revenue trajectory has been positive, but annual growth is likely to moderate as penetration rises in established markets. Future upside depends on diagnosis, global reimbursement, adolescent or additional label opportunities, and continued conversion from enzyme replacement therapy.

What revenue exposure does Amicus have to Galafold?

Galafold remains Amicus’ largest commercial product and a major source of operating cash flow. Concentration creates two opposing effects.

The positive effect is predictability. Fabry disease is chronic, treatment is recurring and switching is generally managed by specialist physicians. The negative effect is concentration risk. A regulatory restriction, safety signal, manufacturing disruption, reimbursement change or successful generic challenge could materially affect Amicus revenue.

The launch of Joenja reduces long-term dependence on Galafold, but it also increases Amicus’ research, commercial and market-access costs. Investors should track Galafold net product sales, patient counts, geographic mix, gross-to-net adjustments and operating expenses rather than revenue alone. [1]

Key Takeaways

• Galafold is Amicus Therapeutics’ oral treatment for adults with Fabry disease and amenable GLA mutations.
• Global revenue reached approximately $403 million in 2023, compared with about $359 million in 2022.
• U.S. FDA approval occurred on May 10, 2018.
• Five-year new chemical entity exclusivity generally ended in 2023.
• Seven-year orphan-drug exclusivity generally runs through May 10, 2025, subject to applicable extensions and statutory conditions.
• Patent protection may continue beyond orphan exclusivity through compound, formulation, method-of-use and manufacturing claims.
• Galafold is not exposed to biosimilar competition because migalastat is a small molecule.
• The most important future entry risk is an ANDA with Paragraph IV certification.
• Generic erosion could be slower than in mass-market drugs because Fabry prescribing is specialist-led and genetically constrained.
• Galafold remains Amicus’ core revenue product, while Joenja is intended to diversify the company’s commercial base.

FAQs About Galafold Market and Patent Risk

What is the active ingredient in Galafold?

The active ingredient is migalastat hydrochloride, an oral pharmacological chaperone for amenable GLA mutations associated with Fabry disease.

Is Galafold a biologic drug?

No. Galafold is a small-molecule drug. Generic entry would generally use the ANDA pathway rather than the biosimilar pathway.

Can all Fabry patients take Galafold?

No. Patients must have a GLA mutation classified as amenable under the applicable regulatory framework. Patients with non-amenable mutations are generally not eligible under the approved U.S. indication.

What is the main commercial advantage of Galafold?

The main advantage is oral administration, which avoids the recurring intravenous infusions required by enzyme replacement therapies for Fabry disease.

What would most threaten Galafold revenue?

The principal threats are a successful Paragraph IV patent challenge, earlier-than-expected generic entry, reduced reimbursement, slower patient diagnosis, loss of mutation-testing momentum and competition from improved enzyme replacement products.

References

1. Amicus Therapeutics, Inc. (2024). Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/ixviewer/doc/action?doc=

2. U.S. Food and Drug Administration. (2018). Galafold prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208623s000lbl.pdf

3. European Medicines Agency. (2024). Galafold: EPAR product information. https://www.ema.europa.eu/en/medicines/human/EPAR/galafold

4. Amicus Therapeutics, Inc. (2023). Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission. https://www.sec.gov/

5. Amicus Therapeutics, Inc. (2022). Form 10-K for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission. https://www.sec.gov/

6. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-drug-designation-and-exclusivity

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.

DrugChatter Q&A for GALAFOLD

Galafold amicus?
Amicus galafold?
What are the side effects of Galafold?